A Phase II Study of Single Agent Sorafenib in Non-Small Cell Lung Cancer Patients Who Never Smoked or Were Former Light Smokers.
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2014
At a glance
- Drugs Sorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 03 Jun 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 23 Nov 2011 Planned end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.